RATIONALE: Protracted use of methamphetamine (mAMPH) can result in long-term impairments in cognitive function in humans. A previous study reported reversal-specific learning impairments in rats after a binge administration of mAMPH. Several studies show that extended exposure to mAMPH may confer protection against cognitive impairments and the insult to monoamine systems typically observed after larger binge doses. OBJECTIVES: To explore this issue, we compared the effects of escalating and single doses of mAMPH (and saline, SAL) on retention, reversal learning, and post-mortem analysis of dopamine and serotonin transporters, DAT and SERT. METHODS: Rats learned to discriminate equiluminant stimuli and then were treated with either: (1) 4 weeks of mAMPH increasing by 0.3 mg/kg, culminating in 6 mg/kg (mAMPH(escal)); (2) 4 weeks of SAL with a single dose of 6 mg/kg on the last day of treatment (mAMPH(single)); or (3) 4 weeks of SAL. Following treatment, rats were tested on retention and reversal learning, with subsequent analysis of DAT and SERT binding across subregions of the striatum and frontoparietal cortex, respectively. RESULTS: Retention of the pretreatment discrimination was not significantly impaired in either mAMPH treatment group. A significant decrease in ventrolateral striatal DAT binding was observed only in the mAMPH(single) group and frontoparietal SERT was unaffected by either mAMPH treatment. Both treatment groups demonstrated attenuated reversal learning, particularly on measures of accuracy and effort. CONCLUSIONS: These results show that extended and single-dose pretreatment with mAMPH similarly and selectively affect reversal learning, even in the absence of significant DAT or SERT changes.
RATIONALE: Protracted use of methamphetamine (mAMPH) can result in long-term impairments in cognitive function in humans. A previous study reported reversal-specific learning impairments in rats after a binge administration of mAMPH. Several studies show that extended exposure to mAMPH may confer protection against cognitive impairments and the insult to monoamine systems typically observed after larger binge doses. OBJECTIVES: To explore this issue, we compared the effects of escalating and single doses of mAMPH (and saline, SAL) on retention, reversal learning, and post-mortem analysis of dopamine and serotonin transporters, DAT and SERT. METHODS:Rats learned to discriminate equiluminant stimuli and then were treated with either: (1) 4 weeks of mAMPH increasing by 0.3 mg/kg, culminating in 6 mg/kg (mAMPH(escal)); (2) 4 weeks of SAL with a single dose of 6 mg/kg on the last day of treatment (mAMPH(single)); or (3) 4 weeks of SAL. Following treatment, rats were tested on retention and reversal learning, with subsequent analysis of DAT and SERT binding across subregions of the striatum and frontoparietal cortex, respectively. RESULTS: Retention of the pretreatment discrimination was not significantly impaired in either mAMPH treatment group. A significant decrease in ventrolateral striatal DAT binding was observed only in the mAMPH(single) group and frontoparietal SERT was unaffected by either mAMPH treatment. Both treatment groups demonstrated attenuated reversal learning, particularly on measures of accuracy and effort. CONCLUSIONS: These results show that extended and single-dose pretreatment with mAMPH similarly and selectively affect reversal learning, even in the absence of significant DAT or SERT changes.
Authors: Antonio Verdejo-García; Antoine Bechara; Emily C Recknor; Miguel Pérez-García Journal: J Int Neuropsychol Soc Date: 2006-05 Impact factor: 2.892
Authors: Stephanie M Groman; Buyean Lee; Emanuele Seu; Alex S James; Karen Feiler; Mark A Mandelkern; Edythe D London; J David Jentsch Journal: J Neurosci Date: 2012-04-25 Impact factor: 6.167
Authors: William F Hoffman; Meredith Moore; Raymond Templin; Bentson McFarland; Robert J Hitzemann; Suzanne H Mitchell Journal: Psychopharmacology (Berl) Date: 2006-08-17 Impact factor: 4.530
Authors: J W Boja; W M Mitchell; A Patel; T A Kopajtic; F I Carroll; A H Lewin; P Abraham; M J Kuhar Journal: Synapse Date: 1992-09 Impact factor: 2.562
Authors: Alicia Izquierdo; Lisa M Wiedholz; Rachel A Millstein; Rebecca J Yang; Timothy J Bussey; Lisa M Saksida; Andrew Holmes Journal: Behav Brain Res Date: 2006-05-19 Impact factor: 3.332
Authors: Alexandra Stolyarova; Andrew B Thompson; Ruth M Barrientos; Alicia Izquierdo Journal: Neuropsychopharmacology Date: 2015-03-13 Impact factor: 7.853
Authors: Stephanie M Groman; Bart Massi; Samuel R Mathias; Daniel W Curry; Daeyeol Lee; Jane R Taylor Journal: J Neurosci Date: 2018-11-09 Impact factor: 6.167
Authors: Alicia Izquierdo; Hilda Pozos; Adrianna De La Torre; Simone DeShields; James Cevallos; Jonathan Rodriguez; Alexandra Stolyarova Journal: Behav Brain Res Date: 2016-04-26 Impact factor: 3.332